Статті в журналах з теми "Heparin Therapeutic use"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Heparin Therapeutic use".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Banik, Nipa, Seong-Bin Yang, Tae-Bong Kang, Ji-Hong Lim, and Jooho Park. "Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules." International Journal of Molecular Sciences 22, no. 19 (September 29, 2021): 10524. http://dx.doi.org/10.3390/ijms221910524.
Повний текст джерелаMycroft-West, Courtney J., Lynsay C. Cooper, Anthony J. Devlin, Patricia Procter, Scott E. Guimond, Marco Guerrini, David G. Fernig, Marcelo A. Lima, Edwin A. Yates та Mark A. Skidmore. "A Glycosaminoglycan Extract from Portunus pelagicus Inhibits BACE1, the β Secretase Implicated in Alzheimer’s Disease". Marine Drugs 17, № 5 (16 травня 2019): 293. http://dx.doi.org/10.3390/md17050293.
Повний текст джерелаBeurskens, Danielle M. H., Joram P. Huckriede, Roy Schrijver, H. Coenraad Hemker, Chris P. Reutelingsperger, and Gerry A. F. Nicolaes. "The Anticoagulant and Nonanticoagulant Properties of Heparin." Thrombosis and Haemostasis 120, no. 10 (August 20, 2020): 1371–83. http://dx.doi.org/10.1055/s-0040-1715460.
Повний текст джерелаLudwig, Ralf. "Therapeutic Use of Heparin beyond Anticoagulation." Current Drug Discovery Technologies 6, no. 4 (December 1, 2009): 281–89. http://dx.doi.org/10.2174/157016309789869001.
Повний текст джерелаKutzner, H., and G. Hesse. "Therapeutic use of lowmolecular weight heparin for capillaritis alba." Phlebologie 37, no. 05 (2008): 259–65. http://dx.doi.org/10.1055/s-0037-1622240.
Повний текст джерелаShaughnessy, SG, E. Young, P. Deschamps, and J. Hirsh. "The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria." Blood 86, no. 4 (August 15, 1995): 1368–73. http://dx.doi.org/10.1182/blood.v86.4.1368.bloodjournal8641368.
Повний текст джерелаHoffman, Nannette B., and David J. Frohnapple. "Heparin Dosing Order Form Use in an Academic-Affiliated Veterans Affairs Medical Center." Journal of Pharmacy Technology 12, no. 6 (November 1996): 276–79. http://dx.doi.org/10.1177/875512259601200609.
Повний текст джерелаBitsadze, V. O., E. V. Slukhanchuk, J. Kh Khizroeva, M. V. Tretyakova, N. V. Pyatigorskaya, S. V. Akinshina, N. A. Makatsariya, et al. "Anticoagulant, anti-inflammatory, antiviral and antitumor properties of heparins." Obstetrics, Gynecology and Reproduction 15, no. 3 (July 9, 2021): 295–312. http://dx.doi.org/10.17749/2313-7347/ob.gyn.rep.2021.216.
Повний текст джерелаSung, Michelle, Jeanine Walenga, Walter Jeske, Omer Iqbal, and Mamdouh Bakhos. "Comparing a New Bovine Source Heparin to the Clinically Used Porcine Heparin for Platelet Function Effects and Heparin-Induced Thrombocytopenia Potential." Blood 132, Supplement 1 (November 29, 2018): 2540. http://dx.doi.org/10.1182/blood-2018-99-118781.
Повний текст джерелаOliynyk, Oleksandr, Wojciech Barg, Anna Slifirczyk, Yanina Oliynyk, Serhij Dubrov, Vitaliy Gurianov, and Marta Rorat. "Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy." Life 11, no. 10 (September 30, 2021): 1032. http://dx.doi.org/10.3390/life11101032.
Повний текст джерелаSullivan, Louisa, Asia N. Quan, Karen J. Richey, and Kevin N. Foster. "513 Continuous Heparin Infusion in Burn Patients on Continuous Renal Replacement Therapy." Journal of Burn Care & Research 42, Supplement_1 (April 1, 2021): S103—S104. http://dx.doi.org/10.1093/jbcr/irab032.164.
Повний текст джерелаMalloy, Katherine M., Tara A. McCabe, and Robert J. Kuhn. "Bivalirudin Use in an Infant With Persistent Clotting on Unfractionated Heparin." Journal of Pediatric Pharmacology and Therapeutics 16, no. 2 (April 1, 2011): 108–12. http://dx.doi.org/10.5863/1551-6776-16.2.108.
Повний текст джерелаBosco, Michael, and Troy Kish. "Hepatotoxicity With Elevated Bilirubin Secondary to Prophylactic Doses of Unfractionated Heparin: A Case Report and Review of Heparin-Induced Hepatotoxicity." Journal of Pharmacy Technology 35, no. 1 (September 28, 2018): 36–40. http://dx.doi.org/10.1177/8755122518803363.
Повний текст джерелаHusted, Steen, Lars Wallentin, Felicita Andreotti, Harald Arnesen, Fedor Bachmann, Colin Baigent, Kurt Huber, et al. "Parenteral anticoagulants in heart disease: Current status and perspectives (Section II)." Thrombosis and Haemostasis 109, no. 05 (2013): 769–86. http://dx.doi.org/10.1160/th12-06-0403.
Повний текст джерелаMelissari, Euthemia, Christopher J. Parker, Noel V. Wilson, Giovanni Monte, Chryso Kanthou, Kieran D. Pemberton, Kypros H. Nicolaides, John J. Barrett, and Vijay V. Kakkar. "Use of Low Molecular Weight Heparin in Pregnancy." Thrombosis and Haemostasis 68, no. 06 (1992): 652–56. http://dx.doi.org/10.1055/s-0038-1646338.
Повний текст джерелаMoore, Bonnie Rush, and Kenneth W. Hinchcliff. "Heparin: A Review of its Pharmacology and Therapeutic Use in Horses." Journal of Veterinary Internal Medicine 8, no. 1 (January 1994): 26–35. http://dx.doi.org/10.1111/j.1939-1676.1994.tb03192.x.
Повний текст джерелаNorth, Angela M., Helen L. Barrett, Karin M. Lust, and Karen M. Whitfield. "Therapeutic heparin during the peripartum period - challenges associated with safe use." Journal of Pharmacy Practice and Research 48, no. 4 (June 21, 2018): 314–19. http://dx.doi.org/10.1002/jppr.1399.
Повний текст джерелаJones, Allison J., Keliana L. O'Mara, Brian J. Kelly, and Ravi S. Samraj. "The Impact of Antithrombin III Use in Achieving Anticoagulant Goals in Pediatric Patients." Journal of Pediatric Pharmacology and Therapeutics 22, no. 5 (September 1, 2017): 320–25. http://dx.doi.org/10.5863/1551-6776-22.5.320.
Повний текст джерелаJain, Amit, Kristen Smit, and Naveen Manchanda. "Increased Use of Direct Thrombin Inhibitor Argatroban In Hospitalized Patients." Blood 116, no. 21 (November 19, 2010): 4398. http://dx.doi.org/10.1182/blood.v116.21.4398.4398.
Повний текст джерелаSchlicht, John R., Lisa Sunyecz, Robert J. Weber, Gary H. Tabas, and Roy E. Smith. "Reevaluation of a Weight-Based Heparin Dosing Nomogram: Is Institution-Specific Modification Necessary?" Annals of Pharmacotherapy 31, no. 12 (December 1997): 1454–59. http://dx.doi.org/10.1177/106002809703101202.
Повний текст джерелаLambert, J. R., S. K. Austin, D. Peebles, and H. Cohen. "Audit of the peri-delivery use of unfractionated heparin in women on therapeutic low-molecular weight heparin." British Journal of Haematology 142, no. 3 (August 2008): 453–56. http://dx.doi.org/10.1111/j.1365-2141.2008.07198.x.
Повний текст джерелаLai, K. N., K. Ho, M. Li, and C. C. Szeto. "Use of Single Dose Low-Molecular-Weight Heparin in Long Hemodialysis." International Journal of Artificial Organs 21, no. 4 (April 1998): 196–200. http://dx.doi.org/10.1177/039139889802100404.
Повний текст джерелаSandoval, Elena, Miquel Lozano, Daniel Pereda, Eduard Quintana, Joan Cid, Ana García-Álvarez, Alejandro Fernández-Cisneros, and Manuel Castellá. "A combined approach to treat heparin-induced thrombocytopaenia before heart transplant." Interactive CardioVascular and Thoracic Surgery 31, no. 6 (November 6, 2020): 881–83. http://dx.doi.org/10.1093/icvts/ivaa196.
Повний текст джерелаSchwiesow, Sarah J., Andrea M. Wessell, and Terrence E. Steyer. "Use of a Modified Dosing Weight for Heparin Therapy in a Morbidly Obese Patient." Annals of Pharmacotherapy 39, no. 4 (April 2005): 753–56. http://dx.doi.org/10.1345/aph.1e300.
Повний текст джерелаPoli, Maura, Domenico Girelli, Annamaria Naggi, Natascia Campostrini, Dario Finazzi, Federica Maccarinelli, Annalisa Castagna, and Paolo Arosio. "Hepcidin Inhibition by Modified Heparins without Anticoagulant Activity." Blood 120, no. 21 (November 16, 2012): 483. http://dx.doi.org/10.1182/blood.v120.21.483.483.
Повний текст джерелаWalenga, Jeanine, Walter Jeske, Sabrina Bertini, Giulia Risi, Michelle Sung, Ambar Farooqui, Cassie Bacher, et al. "Bovine Heparin Demonstrates the Same Interaction with HIT Antibodies As Porcine Heparin." Blood 134, Supplement_1 (November 13, 2019): 2351. http://dx.doi.org/10.1182/blood-2019-127304.
Повний текст джерелаHodgman, Tudy. "A Review of Common Approaches to Heparin Dosing." Journal of Pharmacy Practice 8, no. 1 (February 1995): 39–46. http://dx.doi.org/10.1177/089719009500800105.
Повний текст джерелаPhillips, David E., D. Keith Payne, and Glenn M. Mills. "Heparin-Induced Thrombotic Thrombocytopenia." Annals of Pharmacotherapy 28, no. 1 (January 1994): 43–46. http://dx.doi.org/10.1177/106002809402800108.
Повний текст джерелаCacciapuoti, Federico. "Thrombophilias: therapeutic employment of direct oral anticoagulants in venous hypercoagulable states." Italian Journal of Medicine 14, no. 3 (September 17, 2020): 136–42. http://dx.doi.org/10.4081/itjm.2020.1296.
Повний текст джерелаSimko, Robert J., Faye FW Tsung, and Eric J. Stanek. "Activated Clotting Time Versus Activated Partial Thromboplastin Time for Therapeutic Monitoring of Heparin." Annals of Pharmacotherapy 29, no. 10 (October 1995): 1015–21. http://dx.doi.org/10.1177/106002809502901012.
Повний текст джерелаLukinova, Nina, Mano Venkatesan, and Jill White. "Novel Point-Of-Use FXa Assay For Monitoring Anticoagulant Therapy By Oral Factor Xa Inhibitors and Heparin." Blood 122, no. 21 (November 15, 2013): 4816. http://dx.doi.org/10.1182/blood.v122.21.4816.4816.
Повний текст джерелаGonda, David D., Jared Fridley, Sheila L. Ryan, Valentina Briceño, Sandi K. Lam, MD MBA, Thomas G. Luerssen, and Andrew Jea. "The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients." Journal of Neurosurgery: Pediatrics 16, no. 3 (September 2015): 329–34. http://dx.doi.org/10.3171/2015.1.peds14489.
Повний текст джерелаFortenberry, Yolanda. "Characterization of Antithrombin-Specific RNA Aptamers for Use in Anticoagulant Therapy." Blood 124, no. 21 (December 6, 2014): 4236. http://dx.doi.org/10.1182/blood.v124.21.4236.4236.
Повний текст джерелаCampbell, Christopher T., Lucas Diaz, and Brian Kelly. "Description of Bivalirudin Use for Anticoagulation in Pediatric Patients on Mechanical Circulatory Support." Annals of Pharmacotherapy 55, no. 1 (June 26, 2020): 59–64. http://dx.doi.org/10.1177/1060028020937819.
Повний текст джерелаSoares Ferreira Júnior, Alexandre, Stephen H. Boyle, Maragatha Kuchibhatla, Tomi Akinyemiju, and Oluwatoyosi A. Onwuemene. "Use of therapeutic plasma exchange in heparin‐induced thrombocytopenia: A population‐based study." Journal of Clinical Apheresis 36, no. 3 (January 16, 2021): 398–407. http://dx.doi.org/10.1002/jca.21876.
Повний текст джерелаAl-Eidan, Fahad. "IS THE INCIDENCE TREND OF HEPARIN-INDUCED THROMBOCYTOPENIA DECREASED BY THE INCREASED USE OF LOW-MOLECULAR-WEIGHT-HEPARIN?" Mediterranean Journal of Hematology and Infectious Diseases 7 (April 19, 2015): e2015029. http://dx.doi.org/10.4084/mjhid.2015.029.
Повний текст джерелаAgnelli, G., C. Pascucci, B. Cosmi, and GG Nenci. "Effects of therapeutic doses of heparin on thrombolysis with tissue- type plasminogen activator in rabbits." Blood 76, no. 10 (November 15, 1990): 2030–36. http://dx.doi.org/10.1182/blood.v76.10.2030.2030.
Повний текст джерелаAgnelli, G., C. Pascucci, B. Cosmi, and GG Nenci. "Effects of therapeutic doses of heparin on thrombolysis with tissue- type plasminogen activator in rabbits." Blood 76, no. 10 (November 15, 1990): 2030–36. http://dx.doi.org/10.1182/blood.v76.10.2030.bloodjournal76102030.
Повний текст джерелаNorkin, Igor K., Kristina A. Yurova, Olga G. Khaziakhmatova, Vladimir V. Malashchenko, Denis D. Ligatyuk, Igor A. Khlusov, and Larisa S. Litvinova. "Effects of therapeutic doses of heparin on MSC functional activity in modeling the mechanisms of osteointegration under in vitro cultivation." Journal of Ural Medical Academic Science 19, no. 3 (2022): 231–40. http://dx.doi.org/10.22138/2500-0918-2022-19-3-231-240.
Повний текст джерелаNonaka, Taketoshi, Makoto Harada, Masahiko Sumi, Wataru Ishii, Tohru Ichikawa, and Mamoru Kobayashi. "A Case of Heparin-Induced Thrombocytopenia That Developed in the Therapeutic Course of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis." Case Reports in Rheumatology 2019 (July 22, 2019): 1–4. http://dx.doi.org/10.1155/2019/2724304.
Повний текст джерелаKameneva, M. V., A. S. Parfenov, E. L. Klimanova, S. Khalil, G. I. Nikonov, and I. P. Baskova. "Effects of Heparin and Piyavit on blood rheological properties and platelet aggregation." Kazan medical journal 69, no. 5 (October 15, 1988): 331–34. http://dx.doi.org/10.17816/kazmj98424.
Повний текст джерелаSu, Longxiang, Chun Liu, Dongkai Li, Jie He, Fanglan Zheng, Huizhen Jiang, Hao Wang, et al. "Toward Optimal Heparin Dosing by Comparing Multiple Machine Learning Methods: Retrospective Study." JMIR Medical Informatics 8, no. 6 (June 22, 2020): e17648. http://dx.doi.org/10.2196/17648.
Повний текст джерелаManco-Johnson, Marilyn J., Neil Goldenberg, Lesley G. Mitchell, and Linda J. Jacobson. "Can Heparin-Based Therapy in Children Be Monitored on Samples Drawn Through Ports? An Analysis From Clinical Trials Data,." Blood 118, no. 21 (November 18, 2011): 3365. http://dx.doi.org/10.1182/blood.v118.21.3365.3365.
Повний текст джерелаGarcia Ruiz, Maria Almudena, Francisco Jose Romero Martinez, Estefania Morente Constantin, Margarita Gomez Morales, and Manuel Jurado. "Continued Use of Tinzaparin at Therapeutic Doses for Prophylaxis of Venous Thromboembolism in Patients with Intolerance to Antivitamins K." Blood 126, no. 23 (December 3, 2015): 4735. http://dx.doi.org/10.1182/blood.v126.23.4735.4735.
Повний текст джерелаKoenig, A., K. Norgard-Sumnicht, R. Linhardt, and A. Varki. "Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents." Journal of Clinical Investigation 101, no. 4 (February 15, 1998): 877–89. http://dx.doi.org/10.1172/jci1509.
Повний текст джерелаHippensteel, Joseph A., Wells B. LaRiviere, James F. Colbert, Christophe J. Langouët-Astrié, and Eric P. Schmidt. "Heparin as a therapy for COVID-19: current evidence and future possibilities." American Journal of Physiology-Lung Cellular and Molecular Physiology 319, no. 2 (August 1, 2020): L211—L217. http://dx.doi.org/10.1152/ajplung.00199.2020.
Повний текст джерелаNguyen, Thuy N., Peter Gal, J. Laurence Ransom, and Rita Carlos. "Lepirudin Use in a Neonate with Heparin-Induced Thrombocytopenia." Annals of Pharmacotherapy 37, no. 2 (February 2003): 229–33. http://dx.doi.org/10.1177/106002800303700214.
Повний текст джерелаMonagle, Paul, and Fiona Newall. "Management of thrombosis in children and neonates: practical use of anticoagulants in children." Hematology 2018, no. 1 (November 30, 2018): 399–404. http://dx.doi.org/10.1182/asheducation-2018.1.399.
Повний текст джерелаGhiselli, Giancarlo. "Heparin Binding Proteins as Therapeutic Target: An Historical Account and Current Trends." Medicines 6, no. 3 (July 29, 2019): 80. http://dx.doi.org/10.3390/medicines6030080.
Повний текст джерелаChao, Bo H., Lisa Lepeak, Ticiana Leal, and H. Ian Robins. "Clinical Use of the Low-Molecular-Weight Heparins in Cancer Patients: Focus on the Improved Patient Outcomes." Thrombosis 2011 (April 12, 2011): 1–10. http://dx.doi.org/10.1155/2011/530183.
Повний текст джерела